2026 Interim report
Filed with HKEX · Stock code 2096 · · 93 pages · English
Simcere Pharmaceutical Group Limited on 6ix
Earlier from Simcere Pharmaceutical
- (Revised) Next Day Disclosure Return
- Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
- Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
- Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
- Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage
Later from Simcere Pharmaceutical
- Notification letter and reply form to registered shareholders: notice of publication of interim report 2026
- Notification letter and reply form to non-registered holders: notice of publication of interim report 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Next Day Disclosure Return
- Voluntary announcement - entering into an exclusive promotion services agreement with lynk pharmaceuticals in respect of dermatological indications of zemprocitinib
Follow Simcere Pharmaceutical into a list and get an email when it puts out news.
Follow Simcere Pharmaceutical